TerminatedPhase 4

Hospital Avoidance Strategies for ABSSSI

Stopped: Funding and recruitment limited by pandemic

United States11 participantsStarted 2019-03-04

Plain-language summary

More than 40% of patients presenting with acute bacterial skin and skin structure infection (ABSSSI) to the Barnes-Jewish Hospital (BJH) emergency department (ED) are admitted for intravenous antibiotics. There is growing evidence to suggest that many hospital admissions for uncomplicated ABSSSI due to Gram-positive bacteria could be avoided with an alternative treatment strategy employing newer long-acting antibiotics. Coupled with close outpatient follow-up, such an alternative hospital avoidance strategy has the potential to improve quality and value of care for patients with uncomplicated ABSSSI and optimize use of limited inpatient healthcare resources.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Skin lesion size ≥75 cm2 (measured by area of erythema, edema, and/or induration) AND
✓. Signs of systemic inflammation (at least 1 of the following: WBC \>12,000 or \<4,000 cells/mm3; ≥10% immature neutrophils on peripheral smear; temperature \>38.3˚C or \<36˚C; heart rate \>90 bpm, respiratory rate \>20 bpm). Signs of systemic inflammation not required if the patient is age \>70 years, has diabetes mellitus, or has been treated with immunosuppressive or chemotherapy in the past 90 days.

What they're measuring

Healthcare Utilization Related to ABSSSI

Timeframe: 28 days

Trial details

NCT IDNCT03372941

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-14

Results submitted2022-09-23

View on ClinicalTrials.gov More Skin Infection trials